[ad_1]
- Driven by 14 global brands, reported revenue increased by +18.4% year-on-year, and basic revenue increased by +3.8% year-on-year
- Grew reported an operating profit of 248.6 billion yen ($2.2 USD), a basic core operating profit rate of 30.5%, and increased R&D investment
- In the first quarter, 242.9 billion yen was paid to repay US$2.2 billion in debt. The company expects to prepay a total of approximately 450 billion yen (approximately US$410 million) in debt in the 2021 fiscal year
- It is estimated that there will be 5 to 6 regulatory submissions and 7 new molecular entities in key research at the end of the fiscal year.
- Confirmation of management guidance and forecasts for the full year of fiscal 2021
Takeda Pharmaceutical Co., Ltd. (TYO:4502,New York Stock Exchange:so) (“Takeda”) today announced the financial results for the first quarter of fiscal year 2021 (period ending June 30, 2021). Based on the solid first quarter results, the company also confirmed its management guidance and forecast for the 2021 fiscal year. Fiscal 2021 is still a turning point, and Takeda will achieve top-line acceleration and continued pipeline progress, including key regulatory submissions, potential approvals, and other new molecular entities (NMEs) that are advancing in key research.
Chief Financial Officer Costa Saroukos commented:
“With the integration of Shire and the continuous transformation of the past two years, we have turned to accelerating revenue growth and investing in research and development to promote our highly innovative product line. Takeda’s first quarter results proved the continued success of our 14 global brands. With strength and strength, with the business momentum from this strong start to our fiscal year, we are still expected to achieve full-year management guidance.”
“As we increase our strategic R&D investment and pipeline delivery, fiscal 2021 is a turning point for our pipeline. We expect that there will be 5 to 6 first-wave pipeline regulatory submissions by the end of this fiscal year, and there may be five by the end of the year. Approved for the first half of fiscal year 2022. The resilience of Takeda’s business model is a testament to our unwavering commitment to serving patients, our people, and the planet. We focus on discovering and providing life-changing treatments for people around the world to create And maximize the long-term creation of value for society.”
Financial and business highlights
Results for the first quarter of fiscal year 2021 as of June 30, 2021
|
(Billion yen, excluding percentage and amount per share) |
Report |
nuclear (Non-International Financial Reporting Standards)(A sort of) |
Potential(two) (Non-International Financial Reporting Standards)(A sort of) |
||
|
First quarter of fiscal year 2021 |
Compared with last year |
First quarter of fiscal year 2021 |
Compared with last year |
||
|
income |
949.6 |
+18.4% |
816.6 |
+1.8% |
+3.8% |
|
operating profit |
248.6 |
+48.6% |
248.9(C) |
-11.4% |
-2.1% |
|
profit |
26.2% |
+5.3pp |
30.5% |
-4.5pp |
30.5% |
|
net income |
200.4 |
+142.8% |
176.6 |
-7.4% |
|
|
Earnings per share (yen) |
128 yen |
+141.9% |
113 yen |
-7.7% |
+3.9% |
|
Operating cash flow |
166.9 |
+14.4% |
|
|
|
|
Free cash flow (non-IFRS)(advertise) |
129.9 |
-11.2% |
|
|
|
(a) More information about Takeda’s certain non-IFRS measures is posted on Takeda’s investor relations website https://www.takeda.com/investors/financial-results/.
(b) Basic growth compares the financial performance of two periods (quarterly or annual) on a common basis and is used by management to evaluate the business. These financial results are in fixed currency and do not include…
The full story on Benzinga.com
[ad_2]
Source link
